

Thomas S Larsen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6423946/thomas-s-larsen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91
papers

1,081
citations

18
h-index

31
g-index

94
ext. papers

1,388
ext. citations

3.6
avg. IF

3.89
L-index

#	Paper	IF	Citations
91	Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	0
90	Diagnosis, treatment, and outcome of primary CNS lymphoma-a single-center experience.. <i>Acta Neurochirurgica</i> , 2022 , 1	3	
89	Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma.. <i>Annals of Medicine</i> , 2022 , 54, 713-722	1.5	1
88	Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.. <i>Leukemia and Lymphoma</i> , 2022 , 1-10	1.9	
87	Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2021 , 138, 525-525	2.2	2
86	Safety and efficacy of durvalumab with R-CHOP or R-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2021 , 1	2.3	0
85	The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2021 , 138, 53-53	2.2	0
84	Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 3942-3942	2.2	
83	Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017. <i>British Journal of Ophthalmology</i> , 2021 , 105, 914-920	5.5	5
82	Prognostic models in primary central nervous system lymphoma patients: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 161, 103341	7	
81	Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?. <i>Experimental Hematology</i> , 2021 , 98, 14-24	3.1	0
80	-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than mutation load. <i>Haematologica</i> , 2021 ,	6.6	1
79	Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial. <i>British Journal of Haematology</i> , 2021 ,	4.5	0
78	The clinical applicability of current prognostic models in follicular lymphoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 164, 103418	7	1
77	Harnessing the Immune System to Fight Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6	1
76	Genomic Profiling of a Randomized Trial of Interferon-γ Versus Hydroxyurea in MPN Reveals Mutation-Specific Responses. <i>Blood Advances</i> , 2021 ,	7.8	3
75	Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. <i>Blood Advances</i> , 2020 , 4, 1906-1915	7.8	15

74	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. <i>Leukemia</i> , 2020 , 34, 3256-3268	10.7	17
73	Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models - A Systematic Review. <i>Clinical Epidemiology</i> , 2020 , 12, 537-555	5.9	1
72	Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial. <i>Blood</i> , 2020 , 136, 33-33	2.2	1
71	Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3377-3387	2.2	15
70	Ruxolitinib and interferon- α combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. <i>Haematologica</i> , 2020 , 105, 2262-2272	6.6	33
69	Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. <i>Cancer Medicine</i> , 2020 , 9, 2039-2051	4.8	11
68	Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma - a nationwide population-based cohort study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1950-1957	1.9	1
67	Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2516-2523	1.9	6
66	Pixantrone beyond monotherapy: a review. <i>Annals of Hematology</i> , 2019 , 98, 2025-2033	3	4
65	Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response. <i>Blood</i> , 2019 , 134, 4202-4202	2.2	1
64	Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2019 , 134, 2978-2978	2.2	2
63	Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7520-7520	2.2	7
62	Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study. <i>Blood</i> , 2019 , 134, 5314-5314	2.2	
61	Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2019 , 134, 5396-5396	2.2	
60	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , 2019 , 11, 987-996	5.9	3
59	JAK2V617F but not CALR mutations confer increased molecular responses to interferon- α via JAK1/STAT1 activation. <i>Leukemia</i> , 2019 , 33, 995-1010	10.7	29
58	Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2019 , 102, 227-234	3.8	9
57	Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 133, 1-16	7	3

56	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018 , 93, 57-68	7.5	37
55	Impact of apheresis automation on procedure quality and predictability of CD34 cell yield. <i>Journal of Clinical Apheresis</i> , 2018 , 33, 494-504	3.2	1
54	Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma. <i>British Journal of Haematology</i> , 2018 , 182, 297-301	4.5	5
53	Safety and efficacy of combination therapy of interferon- α and ruxolitinib in polycythemia vera and myelofibrosis. <i>Cancer Medicine</i> , 2018 , 7, 3571-3581	4.8	30
52	Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. <i>European Journal of Cancer</i> , 2018 , 99, 86-96	7.5	42
51	The Impact of Interferon on Interferon-Related Genes in Polycythemia Vera and Allied Neoplasms. <i>Blood</i> , 2018 , 132, 4328-4328	2.2	1
50	Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. <i>Blood</i> , 2018 , 132, 580-580	2.2	10
49	Interferon- α 2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Impacts Deregulation of Oxidative Stress Genes and Antioxidative Defence Mechanisms. Potential Implications of IFN- α Induced Changes in TP53, NRF2 and CXCR4 for Genomic Instability and CD34+ Mobilisation. <i>Blood</i> , 2018 , 132, 4328-4328	2.2	3
48	Extracellular Matrix-Related Genes Are Deregulated in Peripheral Blood from Patients with Myelofibrosis and Related Neoplasms. <i>Blood</i> , 2018 , 132, 5491-5491	2.2	
47	Interferon- α 2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms. <i>Blood</i> , 2018 , 132, 5490-5490	2.2	1
46	Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018 , 132, 1699-1699	2.2	
45	Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study. <i>Blood</i> , 2018 , 132, 607-607	2.2	1
44	Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer. <i>Blood</i> , 2018 , 132, 3071-3071	2.2	0
43	Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment. <i>Epigenomics</i> , 2018 , 10, 1155-1166	4.4	6
42	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 778-784	2.2	48
41	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017 , 75, 195-203	7.5	35
40	The impact of interferon- α 2 on HLA genes in patients with polycythemia vera and related neoplasms. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1914-1921	1.9	12
39	Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2815-2823	1.9	10

38	Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. <i>Scientific Reports</i> , 2017 , 7, 6774	4.9	7
37	Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. <i>Leukemia and Lymphoma</i> , 2016 , 57, 348-354	1.9	28
36	Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1824-36	8.8	8
35	Trends in hematological cancer in the elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , 2016 , 55 Suppl 1, 98-107	3.2	22
34	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1874-1874	2.2	2
33	A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. <i>PLoS ONE</i> , 2016 , 11, e0161570	3.7	2
32	Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial). <i>Blood</i> , 2016 , 128, 1854-1854	2.2	1
31	The Danish National Chronic Myeloid Neoplasia Registry. <i>Clinical Epidemiology</i> , 2016 , 8, 567-572	5.9	7
30	Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. <i>PLoS ONE</i> , 2016 , 11, e0165336	3.7	29
29	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , 2016 , 175, 876-883	4.5	18
28	Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. <i>Lancet Haematology</i> , 2015 , 2, e289-96	14.6	12
27	Primary thymic extranodal marginal zone B cell lymphoma as an incidental finding in a Caucasian woman. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	1
26	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2015 , 126, 3905-3905	2.2	1
25	No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study. <i>Blood</i> , 2015 , 126, 5177-5177	2.2	1
24	Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study. <i>Blood</i> , 2015 , 126, 824-824	2.2	13
23	The Impact of Interferon-alpha2 on HLA-Genes in Patients with Polycythemia Vera and Related Neoplasms. <i>Blood</i> , 2015 , 126, 4097-4097	2.2	
22	Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. <i>PLoS ONE</i> , 2014 , 9, e112786	3.7	45
21	Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. <i>PLoS ONE</i> , 2014 , 9, e85567	3.7	10

20	Primary CNS lymphoma in a patient treated with azathioprine. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	3
19	DNA Methylation Profiling of Sorted Cells from Myelofibrosis Patients reveals Aberrant Epigenetic Regulation of Immune Pathways and identifies Early MPN Driver Genes. <i>Blood</i> , 2014 , 124, 4576-4576	2.2	
18	Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. <i>Leukemia Research</i> , 2013 , 37, 1041-5	2.7	72
17	Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. <i>Current Drug Targets</i> , 2011 , 12, 392-419	3	32
16	Increased Expression of Proteasome-Related Genes In Patients with Primary Myelofibrosis. <i>Blood</i> , 2010 , 116, 4117-4117	2.2	1
15	Enhanced Gene Expression of EZH2 In Patients with Primary Myelofibrosis. <i>Blood</i> , 2010 , 116, 4118-4118	2.2	
14	Gene Expression Profiling with Principal Component Analysis Depicts the Biological Continuum From Essential Thrombocythemia Over Polycythemia Vera to Myelofibrosis. <i>Blood</i> , 2010 , 116, 4115-4115 ^{2,2}		
13	Increased Gene Expression of Histone Deacetylases In Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2010 , 116, 4119-4119	2.2	1
12	High Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule(CEACAM) 6 In Primary Myelofibrosis. <i>Blood</i> , 2010 , 116, 4116-4116	2.2	
11	Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. <i>Hematology</i> , 2009 , 14, 331-4	2.2	65
10	Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. <i>Hematology</i> , 2009 , 14, 11-5	2.2	22
9	High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. <i>Hematology</i> , 2008 , 13, 71-6	2.2	11
8	Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses.. <i>Blood</i> , 2008 , 112, 1744-1744	2.2	1
7	Limited Efficacy of Hydroxyurea in Lowering of the JAK2 V617F Allele Burden.. <i>Blood</i> , 2008 , 112, 1750-1750	2.2	1
6	The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2007 , 136, 745-51	4.5	128
5	Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. <i>Apmis</i> , 2007 , 115, 1267-73	3.4	2
4	A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. <i>Cancer Genetics and Cytogenetics</i> , 2007 , 172, 107-12		10
3	The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. <i>European Journal of Haematology</i> , 2007 , 79, 508-15	3.8	108

- 2 Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). Results from a Danish Multicenter Study.. *Blood*, **2007**, 110, 4641-4641 2.2
- 1 Quantitative PCR Assessment of JAK2 Mutational Status in Philadelphia-Chromosome Negative Chronic Myeloproliferative Disorders - The JAK2 V617F Mutation Is an Event in an Early Stem Cell and the Clonal Involvement of Different Haematopoietic Cells Varies between Individual Patients.. *Blood*, **2006**, 108, 3602-3602 2.2